Shining a light on dry eye opportunities for independents

Positive Impact has announced a new collaboration with Lumenis BE, the leading energy-based medical device company for eye care and aesthetic applications and inventor of intense pulsed light (IPL) technology.

Positive Impact will now provide professional support, education and clinical training in the UK for OptiLight, which will be delivered by its recently expanded team of professional affairs consultants.

OptiLight is the first and only light treatment FDA-approved for the management of dry eye disease due to Meibomian gland dysfunction with its patented Optimal Pulse Technology (OPT).

OptiLight offers targeted, uniform, precise and controlled treatment that safely and effectively breaks the cycle of inflammation associated with dry eye disease and is backed by over 30 peer-reviewed studies.

Positive Impact and Lumenis celebrated the collaboration at 100% Optical last month where both were exhibiting. The companies believe that independent practices can expand their business with OptiLight, offering a new line of treatment for dry eye and a possible upgrade to aesthetic skin treatments.

EMEA Lumenis Vision Sales Director, Paris Hatzianastasiadis, said: “We are delighted to introduce OptiLight to the UK market and offer a root-cause treatment that elevates dry-eye management. With our one-of-a-kind technology, and Positive Impact’s experienced team to support our activities on the ground in the UK, we can improve health and quality of life for dry eye patients.”

Positive Impact Managing Director, Nick Atkins, added: “OptiLight fits perfectly with our business ethos of only working with best-in-class products that offer differentiation and generate sales for the independent practice.

“I have long felt that the future of successful dry eye management, both clinically and commercially, lies with professional in-practice treatment options,” he concluded.